Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (The Swedish TIRA project)

Rheumatology

Volumn 47, Issue 4, 2008, Pages 415-417

  Kastbom, A ^a   Verma, D ^a   Eriksson, P ^a   Skogh, T ^a   Wingren, G ^a   Soderkvist P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Disease course; Genetics; Inflammasome; Rheumatoid arthritis

Indexed keywords

BINDING PROTEIN; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 8; CRYOPYRIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; ETANERCEPT; INFLIXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWEDEN; TIME; WILD TYPE; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049159804     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem372     Document Type: Article

References (21)

1. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl 4):iV2-14.
2. Smeets TJ, Barg EC, Kraan MC et al. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: Comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8.
3. Ulfgren AK, Gröndal L, Lindblad S et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: Potential implications for treatment. Ann Rheum Dis 2000;59:439-47.
4. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26.
5. Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25.
6. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92.
7. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4.
8. Verma D, Lerm M, Blomgran-Julinder R, Eriksson P, Söderkvist P, Sörndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation - relation to common inflammatory diseases? Arthritis Rheum (in press).
9. Hoffman HM, Gregory SG, Mueller JL et al. Fine structure mapping of CIAS1: Identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 2003;112:209-16.
10. McGovern DP, Butler H, Ahmad T et al. TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology 2006;131:1190-6.
11. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
12. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Kastbom A, Ahmadi A, Söderkvist P, Skogh T. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: Increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology 2005;44:1294-8.
15. Fisher SA, Lanchbury JS, Lewis CM. Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: Confirmation of a susceptibility locus on chromosome 16. Arthritis Rheum 2003;48:1200-6.
16. Kummer JA, Broekhuizen R, Everett H et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues, suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007;55:443-52.
17. Rosengren S, Hoffman HM, Bugbee W, Boyle DL. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2005;64:708-14.
18. O'Sullivan BJ, Thomas HE, Pai S et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006;176:7278-87.
19. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
20. Huizinga TW, Amos CI, van der Helm-van Mil AH et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
21. Källberg H, Padyukov L, Plenge RM et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75.